Seeking Alpha

Medgenics (MDGN)

  • Wed, Jun. 24, 12:45 PM
  • Dec. 9, 2014, 5:36 PM
    | Comment!
  • Dec. 8, 2014, 12:45 PM
  • Dec. 5, 2014, 5:40 PM
    | 1 Comment
  • Nov. 25, 2014, 12:45 PM
    | Comment!
  • Nov. 25, 2014, 9:15 AM
    | Comment!
  • Oct. 6, 2014, 12:46 PM
    | Comment!
  • Jul. 9, 2013, 9:46 AM
    Medgenics (MDGN +1.1%) says its wholly owned subsidiary has been awarded a $1.9M grant from the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of Israel. The company says it will use the funds to cover R&D expenses. (PR)
    | 1 Comment
  • Feb. 8, 2013, 11:40 AM
    Medgenics (MDGN -7.3%) slips after pricing its offering of company stock and warrants at $5.25, near current levels. The company says it's bundling the shares and warrants together, with each unit sold at $5.25 consisting of one share of common stock and a warrant to purchase one-half of a share at an initial exercise price of $6.78. The medical technology and therapeutics company said it plans to sell 5.6M shares of stock in order to raise around $29.4M. Maxim Group is acting as sole book-running manager.
    | 1 Comment
  • Dec. 6, 2012, 1:36 PM
    Medgenics (MDGN -1.2%) says it's received a Notice of Allowance from the Japanese Patent and Trademark Office for key claims protecting the use of it's Infradure Biopump technology. The technology provides interferon therapy for the treatment of hepatitis B, C, and D. MDGN has already been granted patents covering core Biopump technology in the U.S. and in the EU.
    | Comment!
  • Nov. 21, 2012, 1:18 PM
    Medgenics (MDGN +13.2%) gets a pop today after being granted a patent by the USPTO protecting the use of the company's Epodure Biopump technology for the treatment of anemia. The patent agency also allowed claims covering a similar method for delivery underlying it's Hemodure Biopump technology for sustained prophylactic treatment of hemophilia. MDGN's global portfolio now includes 36 patents issued, with 81 more pending.
    | Comment!
  • Jun. 20, 2012, 3:08 PM
    Shares of Medgenics (MDGN +25%) soar after the company says its Infradure Biopump has received an Orphan Drug Designation from the FDA to treat hepatitis D. The designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process. Seeking Alpha contributor Ray Dirks says the designation makes it a prime takeout target.
    | Comment!
Visit Seeking Alpha's
MDGN vs. ETF Alternatives
Company Description
Medgenics Inc is a medical technology and therapeutics company. The Company along with its subsidiaries is engaged in the research and development of products in the field of biotechnology and associated medical equipment.
Sector: Healthcare
Industry: Biotechnology
Country: United States